In melanoma patients treated with ICIs including anti‐CTLA4‐antibody and anti‐PD‐1 antibody, high pretreatment levels of serum sPD‐L1 were associated with an increased likelihood of progressive disease in patients treated with ICIs.34 This evidence concerns the gene SPDL1 and melanoma.